| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -20.0 | -22.0 |
| Net income | -20.0 | -22.0 |
| EPS (diluted, $ a share) | $-0.24 | $-0.35 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PYXS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pyxis Oncology, Inc.: key numbers
- Share price
- $1.41Close, Nov 16
- Market cap
- $169M
- Shares outstanding
- 119.61MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pyxis Oncology, Inc.
All →Pyxis Oncology Other 8-K Filing
Pyxis Oncology stockholders approved an amendment to the company's Certificate of Incorporation to double the number of authorized shares of common stock from 190 million to 380 million. The amendment became effective upon filing with the Secretary of State of Delaware on November 13, 2026. No shares were issued or sold as part of this filing, which primarily serves to reserve capacity for future corporate purposes.
Pyxis Oncology Financial Results
Pyxis Oncology reported financial results for the third quarter of 2026, ending the period with $114.3 million in cash and equivalents. The company highlighted progress on its lead candidate, micvotabart pelidotin (MICVO), including alignment with the FDA and EMA on the design of a global Phase 3 trial in head and neck cancer planned for mid-2027.
- Term
- Q3 2026
“The September monotherapy data reinforce our confidence in MICVO’s potential to serve a significant population of patients with previously treated recurrent/metastatic head and neck cancer. We have aligned with feedback received from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the design of the global Phase 3 Headliner trial and plan to initiate it in mid-2027, with FDA feedback on dose selection expected in the first quarter of 2027.”
Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology
Pyxis Oncology Capital Raise of $110M
Pyxis Oncology closed an underwritten public offering of 36,047,919 shares of common stock and pre-funded warrants, along with accompanying common warrants, at a combined price of $2.90 per share. The offering raised approximately $110 million in gross proceeds before expenses. The common warrants will only become exercisable upon stockholder approval of a charter amendment to increase the company's authorized share count.
- Value
- $110M
- Counterparty
- Leerink Partners LLC, Guggenheim Securities, LLC and Wells Fargo Securities, LLC